Enliven Therapeutics Inc (ELVN) returns
Enliven Therapeutics returns over 5 years
$1,000 invested in Enliven Therapeutics five years ago was worth $3,073 at the close on October 30, 2026, with dividends reinvested: an average return of 25.2% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -3.5% | — | $965.31 | -0.9% |
| 3 months | -18.0% | — | $820.20 | +2.1% |
| Year to date | +187.3% | — | $2,873 | +11.7% |
| 1 year | +84.6% | — | $1,846 | +12.4% |
| 3 years | +269.1% | +54.5% | $3,691 | +88.5% |
| 5 years | +207.3% | +25.2% | $3,073 | +76.0% |
Enliven Therapeutics return by calendar year
| Year | ELVN | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | +187.3% | +11.7% | +175.6% |
| 2025 | -31.6% | +17.7% | -49.3% |
| 2024 | +62.6% | +24.9% | +37.7% |
| 2023 | -15.4% | +26.2% | -41.6% |
| 2022 | +81.8% | -18.2% | +99.9% |
| 2021 | -89.8% | +28.7% | -118.5% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also:
No forecast, no recommendation. This page describes Enliven Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.